StockData
Biodesix Inc logo

Biodesix Inc (BDSX) bonds

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$9.88+0.09 (+0.92%)

Close on Nov 13, 2026Market cap $104.25MP/E –Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Total debt
$47.15M
Long-term debt
Net debt
$18.74M
After $28.41M of cash
Implied interest rate
18.40%
FY2025 interest ÷ average debt
Interest coverage
-3.6×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Biodesix's 10-Q for the period ended Nov 21, 2027

IssueCouponMaturesCarrying value
Perceptive Term Loan Facility3.00%Nov 21, 2027–
Other––$6.00K
Perceptive Term Loan Facility––$50.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?